Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2017
Price : $35 *
At a glance
- Drugs Eculizumab (Primary) ; Immune globulin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 02 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 19 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 20 Apr 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2016 according to ClinicalTrials.gov record.